Capricor Faces Securities Fraud Class Action Over Deramiocel Trial Data
CAPR has more than doubled off its 52-week low of $2.96 on light trading volume (0.1× avg).
Summary
A securities fraud class action has been filed against Capricor, with a lead plaintiff deadline of September 28, 2026. The lawsuit alleges the company made misleading statements about Deramiocel's clinical trial data and failed to disclose unagreed-upon changes to its statistical analysis plan before resubmitting its BLA. The class period runs from December 17, 2025 to July 26, 2026, covering the 370% surge after the HOPE-3 topline announcement and the subsequent 64% crash when FDA briefing documents revealed the SAP modifications. This legal action adds to the company's existing regulatory uncertainty following the FDA advisory committee's 9-3 vote against deramiocel's effectiveness. The lawsuit's core allegation—that management misrepresented trial endpoints—directly challenges the integrity of the data underpinning the company's lead product candidate.
At the time of this announcement, CAPR was trading at $7.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $450.9M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.